The Administration’s Council of Economic Advisors (CEA) has released an analysis of savings expected from its “Most Favored Nation” deals with pharmaceutical manufacturers, but […]
Exaggerated MFN cost-saving estimates imperil U.S. innovation and investment Read More »
Key takeaway: PDUFA enables the FDA to collect user fees from the biopharmaceutical industry, allowing for efficient and more predictable reviews. This funding model
What is PDUFA—and why does it matter for biotech innovators, FDA & patients? Read More »
At some point in our lives, many of us will find ourselves in a health fight we didn’t expect. A diagnosis. A test result.
Voters see a better path than Most Favored Nation to ensure access and affordability of innovative medicines Eight in 10 American voters would be
Poll: U.S. voters want PBM and insurance reform—and strong biotech Read More »
With health care affordability a top concern for many Americans, pharmacy benefit managers (PBMs) continue to stand at the center of the debate. Working
The hidden layer of PBMs: What a recent investigation reveals Read More »
Americans are frustrated with the health care system for two reasons. First, it costs too much. But—second—it provides too little. While most of the
Nearly half of Americans say insurers’ rules on access delayed, denied, or altered care Read More »
European countries don’t just pull prices for medicines out of thin air. The prices that those governments set are based on specific sets of
It is often taken as a given that drug prices in the U.S. are higher than those in other nations. And while there is
Putting Americans First: International prices in context Read More »
The most notable differences between the pharmaceutical market in the U.S. and those in other countries are not in the prices. They’re in the
The One Big Beautiful Bill Act – the “reconciliation bill” being considered by Congress – features policies that are crucial for driving American innovation.
